Combination of (a) a DNA topoisomerase inhibitor and (b) an IAP inhibitor

Details for Australian Patent Application No. 2005210137 (hide)

Owner Novartis AG

Inventors Zawel, Leigh

Agent Davies Collison Cave

Pub. Number AU-B-2005210137

PCT Pub. Number WO2005/074989

Priority 60/541,984 05.02.04 US

Filing date 4 February 2005

Wipo publication date 18 August 2005

Acceptance publication date 4 June 2009

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

A61K 31/401 (2006.01) - Proline

A61K 31/4745 (2006.01)

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

Event Publications

3 August 2006 PCT application entered the National Phase

  PCT publication WO2005/074989 Priority application(s): WO2005/074989

4 June 2009 Application Accepted

  Published as AU-B-2005210137

1 October 2009 Standard Patent Sealed

2 September 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005210140-Combination of benzothiazol-2-one beta2 adrenoceptor agonists and corticosteroids for the treatment of respiratory diseases

2005210136-Casing for a blister package